NKGen Biotech, Inc. (NKGN)
OTCMKTS · Delayed Price · Currency is USD
0.1400
0.00 (0.00%)
Aug 1, 2025, 2:35 PM EDT
NKGen Biotech Company Description
NKGen Biotech, Inc., a clinical-stage biotechnology company, develops cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells.
Its lead products include SNK01, an autologous NK cell therapy candidate for the treatment of neurodegenerative diseases, and SNK02, an allogeneic NK cell therapy for refractory solid tumors.
The company has a license agreement with NKMAX for its NK cell program. The company has a strategic partnership with HekaBio K.K. for the development of the company's autologous NK cell therapy, troculeucel, in Japan.
The company was formerly known as NKMAX America, Inc. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California.
NKGen Biotech, Inc.
| Country | United States |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 63 |
| CEO | Paul Y. Song |
Contact Details
Address: 3001 Daimler Street Santa Ana, Delaware 92705 United States | |
| Phone | 949-396-6830 |
| Website | nkgenbiotech.com |
Stock Details
| Ticker Symbol | NKGN |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US65488A1016 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Paul Y. Song M.D. | Chief Executive Officer and Chairman |
| Dr. Yong Man Kim Ph.D. | Chief Scientific Officer |
| James A. Graf | Interim Chief Financial Officer |
| Yoonmi Kang | SVice President of Technical Ops and Development |
| Irene Chang | SVice President, Human Resources and Corporate Culture |
| Denise A. Chua CLS, MBA, MT (ASCP) | SVice President of Corporate Affairs |
| Ryan Park C.F.A. | Executive Vice President of FP&A, Corporate Planning and Strategy |